Background: High platelet reactivity (HPR) after clopidogrel treatment is linked to an increased risk of periprocedural myocardial infarction (PMI). The occurrence of PMI that could be associated with CYP2C19 genotype status was our hypothesis.
eriprocedural myocardial infarction (PMI) is common after percutaneous coronary interventions (PCI) and is associated with worse prognosis. 1-4 Visible adverse events, such as side-branch occlusion, dissection, disruption of collateral flow, and distal embolization during PCI, would likely result in PMI. 2-4 However, most of PMI occurred silently after uneventful PCI. 4 It has been demonstrated that platelet activation and aggregation play pivotal roles in the pathophysiological development of ischemic events during PCI and that pretreatment with clopidogrel has significantly reduced PMI. 5, 6 Of note, variability in response to the fixed dose of clopidogrel is well established. 7, 8 The CYP2C19 loss-of-function (LOF) allele has been identified as a genetic determinant of variant response to clopidogrel. 9-12 For CYP2C19, the most well known common variant is the LOF *2 variant, which generates less amounts of the active metabolite of clopidogrel, resulting in a decreased antiplatelet effect. CYP2C19*3, the next frequent CYP2C19 variant allele in East Asian patients, is also an independent risk factor of high on-clopidogrel platelet reactivity in East Asian patients. 11 These 2 LOF alleles account for almost 100% of the poor metabolizers in Oriental populations. [13] [14] [15] Given that high residual platelet reactivity after clopidogrel treatment is linked to an increased risk of PMI, 16-19 we hypothesized that the occurrence of PMI would be associated with CYP2C19 genotype status. To address this issue, the study was conducted to investigate whether CYP2C19 LOF alleles are associated with PMI after uneventful PCI in Chinese patients. WU H et al.
Methods

Study Population
From February 2011 to November 2011, a total of 447 Chinese patients with acute coronary syndrome (ACS) undergoing PCI were enrolled to investigate the relationship between genetic variants and clopidogrel response. Of the total cohort, 233 patients with non-ST elevation ACS undergoing uneventful elective PCI were included in this analysis due to available periprocedural cardiac necrosis markers and feasibility of determining the occurrence of PMI. In patients with increased baseline concentrations of creatine kinase-MB, the values should be stable or falling before the PCI procedure. Patients with adverse events, including side-branch occlusion, dissection, disruption of collateral flow, suspected thrombus, and coronary perforation during PCI, were not included. Exclusion criteria were: age less than 18 years, concomitant administration of cilostazol, allergies or contraindications to either aspirin or clopidogrel, upstream or bail-out use of glycoprotein IIb/IIIa inhibitors, malignancies, pregnancy, severe renal insufficiency (glomerular filtration rate, GFR, <30 ml · min -1 · 1.73 m -2 ), severe hepatic infufficiency (total bilirubin >2× upper limit of normal, in association with alanine aminotransferase >3× upper limit of normal), total platelet count <100×10 9 /L, increased risk of bleeding, and hematologic disorder. The study protocol was approved by the hospital's medical ethics committee, and informed consent was obtained from each patient.
All patients received drug-eluting stents and dual antiplatelet therapy. A loading dose of 300 mg clopidogrel was encouraged 16 h before the procedure and a daily regimen of 75 mg was given. Patients received a loading dose of 300 mg aspirin followed by 100 mg daily. Technicalities of the procedure, including use of anticoagulation drugs and type of stents, were left to the operator's discretion. Sirolimus-eluting, Zotarolimuseluting, Paclitaxel-eluting, and Everolimus-eluting stents were used in our study. 
Genotyping
Genomic DNA was extracted from whole-blood samples using the Qiagen Blood Kit (Qiagen, Chatsworth, CA, USA), according to the manufacturer's instructions. DNA microarray (gene chip) method was used to evaluate the genotypes of CYP2C19. The CYP2C19*2 and CYP2C19*3 variant alleles were determined with BaiO BE-2.0 Biochip diagnostic Analyzer (BaiO Technology Corp, Shanghai, China). The procedures of DNA extraction, polymerase chain reaction amplification, hybridization, gene array detection, and analysis were strictly according to the manuals of BaiO genotype detecting gene array kit and equipment (BaiO Technology Corp). These 2 polymorphisms were in Hardy-Weinberg equilibrium (P>0.05). Participants were divided into 3 groups, based on the number of the CYP2C19 LOF allele: no LOF carriers (CYP2C19*1/*1), 1 LOF carriers (CYP2C19*1/*2 and CYP2C19*1/*3), and 2 LOF carriers (CYP2C19*2/*2, CYP2C19*2/*3, and CYP2C19*3/*3). No carrier of CYP2C19*3/*3 was found in the study population.
Main Outcomes
The main outcomes of the study included high platelet reactivity (HPR) and PMI. The cut-off points for HPR were defined as ≥70% ADP-induced aggregation with 2-μmol/L ADP as measured by TEG. 20 All patients below these cut-off points were defined as exhibiting normal on-treatment platelet reactivity. PMI was defined as a post-procedural increase in troponin T ≥3 times (≥0.09 ng/ml) the 99 th percentile the upper reference limit for patients with baseline negative myocardial necrosis markers. 22 In patients with increased baseline concentrations of creatine kinase-MB, if the values are stable or falling, a subsequent increase ≥50% the baseline value fulfilled the criteria for periprocedural MI. 23, 24 Blood samples were drawn from all patients before PCI and at 24 h after intervention for measurement of creatine kinase-MB and troponin T concentrations.
Statistical Analyses
Continuous variables were expressed as mean ± SD. Categorical variables were expressed as frequencies and percentage. For analysis of relationship between categorical variables we used the chi-square test or Fisher's exact test when appropriate. Kolmogorov-Smirnov test was used to check for normal distribution of continuous data. T-test or Wilcoxon rank sum test for unpaired samples was used to compare any continuous variable with a normal or non-normal distribution, respectively. Univariate and multivariate logistic regression analysis was performed to determine the significant factors indicating the occurrence of PMI. All tests were 2-sided with a significance level of P<0.05. All statistical analyses were performed with SPSS software package, version 17 (SPSS Inc, Chicago, IL, USA).
Results
Demographic and baseline clinical characteristics in these cohorts are shown in Table 1 , as well as the procedural variables. PMI was documented in 33 of 233 patients (14.2%). Compared with patients without PMI, those with PMI were significantly older and exhibited a considerably higher prevalence of diabetes mellitus ( Table 1) . No significant differences in gender, body mass index, or baseline medications existed between the 2 groups. Likewise, the proportion of patients with hypertension, hypercholesterolemia, current smoking, or history of stroke did not differ significantly. No significant differences between the 2 groups were observed with respect to targeted coronary artery and the number and length of implanted stents.
Mean platelet aggregation was significantly higher in patients with PMI than in those without PMI as measured by TEG (60.0±24.4% vs. 43.0±24.0%, P<0.001; Table 1 ). Compared with subjects without PMI, patients with PMI had a significantly higher prevalence of HPR (42.4% vs. 13.0%, P<0.001; Table 1 ). Moreover, the distribution of CYP2C19 LOF alleles differed significantly between the 2 groups in Table 1 . As demonstrated in Figure 1 , 2 LOF carriers had an increased incidence of PMI compared to no LOF carriers (27.0% vs. 10.7%, P=0.023). An increased incidence of PMI was also observed in 2 LOF carriers compared with 1 LOF carrier (27.0% vs. 12.5%, P=0.037; Figure 1 ). However, there was no significant difference in the prevalence of PMI between no LOF carriers and 1 LOF carrier (10.7% vs. 12.5%, P=0.701; Figure 1 ).
Univariate and multivariate logistic regression analyses were performed to determine the significant factor indicating the occurrence of PMI ( Table 2) . Furthermore, the univariate risk factors which could be assessed before PCI, including age, diabetes mellitus, and CYP2C19 genotype, were entered into the multivariate analysis. After adjustment for confounding factors, the risk for developing PMI still increased by the presence of 2 CYP2C19 LOF alleles (ORadj=3.000, 95% CI: 1.071-8.400, P=0.037; Table 2 ). However, when HPR was included as a covariate in the multivariate logistic regression model, HPR and diabetes mellitus were independent risk factors of PMI, whereas there was no significant relationship between the carriage of 2 CYP2C19 LOF alleles and PMI. When we analyzed the incidence of HPR with respect to the CYP2C19 LOF allele status, we found that 27.0% (10/37) of 2 LOF carriers were classified as HPR, and 19.6% (22/112) of 1 LOF carrier were categorized as HPR, whereas only 9.5% (8/84) of no LOF carriers were identified as HPR (P=0.039; Figure 2 ). Additionally, compared with no LOF carriers, 2 LOF carriers had a 3.519-fold increased risk (95% CI: 1.258-9.838, P=0.016) for HPR. However, the carriage of 1 LOF allele was not significantly associated with the prevalence of HPR (OR=2.322, 95% CI: 0.978-5.515, P=0.056).
Discussion
The present study was conducted for the first time to investigate the influence of CYP2C19 LOF alleles on periprocedural outcomes in patients receiving clopidogrel pretreatment and undergoing PCI. Even though the study population underwent successful and uneventful PCI, PMI still occurred in 14.2% of cases. In line with previous evidence, our study demonstrated that HPR was associated with an increased risk for periprocedural myocardial injury. Furthermore, our study demonstrated that patients carrying 2 CYP2C19 LOF alleles had a more than 3-fold increased risk for PMI in the univariate and multivariate logistic regression analysis. However, inclusion of HPR as a covariate in the multivariate regression model changed the significant relationship between the CYP2C19 LOF allele carriage and PMI. When we analyzed the incidence of HPR with respect to the CYP2C19 LOF allele status, we found that only the carriage of 2 CYP2C19 LOF alleles was significantly associated with the prevalence of HPR. These observations suggest that the effect of CYP2C19 genotype on PMI might be mediated through platelet reactivity.
There is controversy surrounding the issue as to whether PMI is associated with poor clinical outcome. 25, 26 In a recent metaanalysis applying the universal definition of periprocedural MI (type 4a), patients with type 4a MI had an increased risk of major adverse cardiac events compared with those without troponin elevation at an average follow-up of about 17.7 months (OR=2.25, 95% CI: 1.26-4.00, P=0.006). 27 Troponin elevation following PCI could be attributed to extrinsic and intrinsic mechanisms. Visible procedural-related adverse events, such as side-branch occlusion, dissection, disruption of collateral flow, and distal embolization, have been identified as extrinsic factors leading to PMI. 2-4 Recently, accumulative evidences showed that intrinsic platelet activation played a pivotal role in the pathophysiological development of PMI 5, 6 and that pretreatment with clopidogrel has significantly decreased the risk of PMI. 6 Accordingly, current common clinical practice is pretreatment with a 300-mg loading dose of clopidogrel at least 6 h before the procedure in patients undergoing elective intervention. Wide response variability has been observed in patients treated with clopidogrel. Moreover, poor response to clopidogrel is associated with an increased risk for periprocedural myocardial necrosis. [16] [17] [18] [19] Our results support these findings in Chinese patients and show that HPR is the strongest risk factor for PMI. Given the risks associated with decreased clopidogrel responsiveness, alternative treatment strategies, either higher clopidogrel dosing regimens, or upstream use of glycoprotein IIb/IIIa inhibitors, or selection of a novel platelet ADP P2Y12 receptor antagonist, might be considered in patients with HPR. However, it is embarrassing that the anti-platelet effect of clopidogrel could be assessed only after clopidogrel intake, even after PCI.
CYP2C19 genotype has been repeatedly reported to be associated with the HPR phenotype. CYP2C19*2 (containing a splicing defect) and CYP2C19*3 (containing a premature stop codon), are 2 major LOF alleles of CYP2C19. A recent Korean study 12 suggested that CYP2C19 LOF alleles had a gene-dose effect on post-clopidogrel platelet reactivity and that the effect of the CYP2C19*2 vs. *3 LOF allele carriage on platelet reactivity did not differ in East Asians. Additionally, there is no difference in the prevalence of HPR between CYP2C19*2/*2 and CYP2C19*2/*3 carriers. 12 The fact that the magnitude of platelet reactivity increased by the presence of CYP2C19 LOF alleles encourages the search for the additional effect of CYP2C19 genotype on periprocedural outcome during PCI.
We demonstrated that the status of CYP2C19 LOF allele was associated with the occurrence of PMI after uneventful PCI in Chinese ACS patients and that the carriage of 2 CYP2C19 LOF alleles was a significant factor indicating the occurrence of PMI. Thus, our current data seems to support the strategy of CYP2C19 genotyping as a way to identify patients who might be at risk for periprocedural myocardial necrosis. Although the effect of HPR on PMI surpassed the genotype of CYP2C19 and the effect of CYP2C19 genotype on PMI might be mediated through platelet reactivity, genotyping has potential advantages for the optimization of antiplatelet therapy before PCI. Independent of clopidogrel intake, CYP2C19 genotyping might give an estimate of the probability of a low response to clopidogrel and provide an opportunity for physicians to individualize antiplatelet therapy before PCI.
In this observational study, we cannot completely exclude possible bias by various risk factors and patient characteristics although the multivariable adjustment models confirmed the primary analyses. The present study has limitations that merit mention. First, this study was a single-center investigation, which might be limited in making definite conclusion. Second, sample size calculation was not performed in our study. Third, we are aware that using only 1 method to test platelet function might not be sufficient to fully diagnose the response to antiplatelet therapy. Finally, we did not assay platelet reactivity before clopidogrel treatment. Additionally, this study concerns Chinese patients, a population characterized by a high prevalence of the CYP2C19 LOF allele, hence, the results cannot be generalized to the western populations.
Conclusions
In Chinese patients with non-ST elevation ACS, carriers with
